ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View 2020/01/14 06:22:00 Zacks Investment Research
ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.
10 Worst Performing S&P 500 Stocks Of 2019 2019/12/24 16:18:36 Benzinga Feeds
The S&P 500 had another big year this year, gaining more than 28% year to date. Most U.S. investors had a lot of winners in their portfolios this year, but not all companies were along for the bull market ride. Here’s a look at the 10 worst-performing stocks in the entire S&P 500 in 2019, as of the Dec. 20 closing price. 1. Fossil Group Inc (NASDAQ: FOSL ) Fossil investors have been on a rollercoaster ride in the past few years, and 2019 was mostly a free-fall, with the watchmaker’s stock dropping 51.1%. 2. ABIOMED, Inc. (NASDAQ: ABMD ) An FDA letter about the safety of ABIOMED’s Impella RP device wasn’t enough to eliminate market skepticism in 2019, and ABIOMED shares tumbled 49.8%. 3. Macy's Inc (NYSE: M ) Investors seem to be increasingly concerned that Macy’s is heading down the same long-term path as Sears Holdings … Full story available on Benzinga.com
Global Ventricular Assist Devices Market 2020-2024 | Evolving Opportunities with Abiomed Inc. and CorWave SA | Technavio 2019/12/03 14:00:00 Business Wire
LONDON--(BUSINESS WIRE)-- #Healthcare--Global ventricular assist devices market is poised to grow by USD 943.27 million during 2020-2024 at a CAGR of almost 12% during the forecast period.
Abiomed Medical Office Completes Review of Observational Analysis of Impella Presented at AHA 2019/11/19 18:11:00 Benzinga Feeds
Abiomed (NASDAQ: ABMD ) is committed to improving patient outcomes by performing FDA studies and post-market surveillance, collecting real-world evidence and identifying and sharing best practices. Impella is the most studied mechanical circulatory support device in the history of the FDA with real-world clinical data on more than 110,000 patients in the Impella Quality (IQ) Database, FDA randomized controlled trials (RCT) and post-approval studies with greater than 5,000 patients, and more than 550 peer-reviewed publications. Impella is proven to provide superior hemodynamic support over the intra-aortic balloon pump (IABP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005932/en/ Figure 1: Clinical Variables Poorly Matched in Amin, et al. (Graphic: Business Wire) Today the Abiomed medical office is issuing a publication review of the observational analysis of Impella that was presented by Amin et al. at the American Heart Association Conference (AHA) on November 17.
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy? 2019/10/24 14:32:25 Zacks Investment Research
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abiomed, Inc. (ABMD) CEO Michael Minogue on Q1 2019 Results - Earnings Call Transcript 2019-05-02
Abiomed, Inc. (ABMD) Q1 2019 Earnings Conference Call May 02, 2019, 08:00 ET Company Participants Ingrid Ward - Director, IR Michael Minogue - Chairman, CEO & President Todd Trapp - CFO & VP Conference Call Participants Danielle Antalffy - SVB Leerink Bruce Nudell…
ABIOMED, Inc. 2019 Q4 - Results - Earnings Call Slides 2019-05-02
The following slide deck was published by ABIOMED, Inc. in conjunction with their 2019 Q4 earnings Read more …
ABMD, FLR and W among premarket losers 2019-05-02
Eventbrite (NYSE: EB ) -34% on Q1 earnings . More news on: Eventbrite, Inc., VistaGen Therapeutics, Inc., ABIOMED, Inc., Stocks on the move, Read more …
Abiomed on go with large study to assess Impella CP in STEMI heart attacks 2019-05-02
The FDA has signed off on a 668-subject clinical trial evaluating Abiomed's (NASDAQ: ABMD ) Impella CP heart pump in patients undergoing treatment for a type of heart attack called an ST-elevation myocardial infarction (STEMI). More news on: ABIOMED, Inc., Healthcare stocks news, Stock…